NCT06395909View on ClinicalTrials.gov

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

113

Participants

Timeline

Start Date

April 23, 2023

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
Relapsing Multiple SclerosisClinically Isolated SyndromeRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY